The Role of the Immune Response in Controlling the Size of the HIV Reservoir.
免疫反应在控制艾滋病病毒库大小中的作用。
基本信息
- 批准号:8210252
- 负责人:
- 金额:$ 23.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-20 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAntiviral TherapyBiological AssayCD4 Positive T LymphocytesCD8B1 geneCategoriesCell CycleCellsChronicCytolysisCytotoxic T-LymphocytesDNADataFrequenciesFutureGoalsGrantHIVHIV InfectionsHighly Active Antiretroviral TherapyImmuneImmune responseIn VitroIndividualInfectionInvestigationLeadLiteratureLymphocyte FunctionMeasuresMonitorMorbidity - disease ratePatientsProteinsProvirusesRNAResearchResistanceRestRoleSecondary toT-LymphocyteTestingTimeViralViral Load resultViruscell typeexhaustionin vitro Modelin vivomortalitypressureprotein expressionresearch study
项目摘要
DESCRIPTION (provided by applicant): HIV-infected individuals accumulate a reservoir of treatment-resistant, latently infected resting CD4+ T cells. A special category of HIV infected individuals called elite suppressors have undetectable viral loads in the absence of highly active antiretroviral therapy (HAART) and have a smaller HIV reservoir. There is compelling evidence that elite suppressors (ES) have higher functioning CTL activity against HIV than treated and untreated chronic progressors. Our recent data provide evidence that CTL in ES have activity against latently infected resting CD4+ T cells in vivo. Specifically, we demonstrate for the first time that ES patients have dramatically lower levels of integrated HIV DNA and a relatively large excess of unintegrated HIV DNA compared to HAART patients. This is consistent with CTL pressure since HIV proteins are expressed more efficiently from integrated compared to unintegrated HIV DNA. In addition, we have preliminary data that latently infected resting CD4+ T cells express HIV proteins but do not permit spreading infection and thus should be susceptible to CTL pressure. At the same time, we show with our in vitro model of latency that CTL have activity against latently infected resting CD4+ T cells. Thus, the range of CTL targets is greater than previously thought since it appears that latently infected cells can be targets of CTL. In this application, we plan to test for further evidence of CTL pressure by assessing the frequency of HIV RNA+ cells among resting CD4+ T cells in ES vs HAART patients. We expect the frequency of HIV RNA+ cells normalized to integration to be lower in ES because we expect the majority of HIV RNA+ cells will express protein and be subjected to CTL lysis. Finally, we will determine if integration levels increase over time (as suggested by our preliminary data) in all or a subset of ES and if an increase in integration levels correlates with a loss of CTL function in ES. We also consider the alternate hypothesis that integration levels may increase over time in ES because defective proviruses accumulate.
PUBLIC HEALTH RELEVANCE: A special category of HIV infected individuals, called elite suppressors, control HIV viral load to undetectable levels in the absence of antiviral therapy. The proposed experiments investigate the mechanism behind the ability of elite suppressors to maintain a smaller reservoir. Our studies suggest that elite suppressors have immune activity against treatment resistant reservoir cells and may lead to future therapies that harness the immune response to reduce reservoir size in patients receiving antiviral therapy.
描述(由申请方提供):HIV感染个体积累了一个耐药、潜伏感染的静息CD4+ T细胞库。一种特殊类别的HIV感染者称为精英抑制者,在没有高效抗逆转录病毒治疗(HAART)的情况下,病毒载量无法检测到,并且HIV储存量较小。有令人信服的证据表明,精英抑制(ES)具有更高的功能CTL活性对艾滋病毒比治疗和未治疗的慢性进展。我们最近的数据提供了证据,CTL在ES细胞对潜伏感染的静息CD4+ T细胞在体内的活动。具体来说,我们首次证明,ES患者有显着较低水平的整合的HIV DNA和相对较大的过量的未整合的HIV DNA相比,HAART患者。这与CTL压力一致,因为与未整合的HIV DNA相比,整合的HIV DNA更有效地表达HIV蛋白。此外,我们有初步数据表明,潜伏感染的静息CD4+ T细胞表达HIV蛋白,但不允许传播感染,因此应该对CTL压力敏感。同时,我们用我们的体外潜伏模型表明CTL对潜伏感染的静息CD4+ T细胞具有活性。因此,CTL靶的范围比以前认为的更大,因为似乎潜伏感染的细胞可以是CTL的靶。在本申请中,我们计划通过评估ES与HAART患者中静息CD4+ T细胞中HIV RNA+细胞的频率来测试CTL压力的进一步证据。我们预期在ES中归一化为整合的HIV RNA+细胞的频率较低,因为我们预期大多数HIV RNA+细胞将表达蛋白质并进行CTL裂解。最后,我们将确定整合水平是否随时间增加(如我们的初步数据所示)在所有或一个子集的ES,如果在整合水平的增加与CTL功能的丧失ES。我们还考虑了另一种假设,即整合水平可能会随着时间的推移在ES,因为有缺陷的前病毒积累。
公共卫生关系:一类特殊的HIV感染者,称为精英抑制者,在没有抗病毒治疗的情况下将HIV病毒载量控制在无法检测的水平。所提出的实验研究精英抑制子维持较小水库的能力背后的机制。我们的研究表明,精英抑制因子对治疗耐药的储库细胞具有免疫活性,并可能导致未来的治疗方法,利用免疫反应来减少接受抗病毒治疗的患者的储库大小。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Una T O'Doherty其他文献
Una T O'Doherty的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Una T O'Doherty', 18)}}的其他基金
The barcode project: a strategy to track the early naïve reservoir
条形码项目:追踪早期幼稚水库的策略
- 批准号:
10762820 - 财政年份:2023
- 资助金额:
$ 23.1万 - 项目类别:
Determinants of reservoir contraction and expansion in vivo, ex vivo, and in vitro
体内、离体和体外储库收缩和扩张的决定因素
- 批准号:
10358573 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Determinants of reservoir contraction and expansion in vivo, ex vivo, and in vitro
体内、离体和体外储库收缩和扩张的决定因素
- 批准号:
10579911 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Determinants of reservoir contraction and expansion in vivo, ex vivo, and in vitro
体内、离体和体外储库收缩和扩张的决定因素
- 批准号:
10022993 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Unveiling the chromosomal address of intact HIV clones to provide insights into persistence
揭示完整 HIV 克隆的染色体地址,以提供对持久性的见解
- 批准号:
9790462 - 财政年份:2019
- 资助金额:
$ 23.1万 - 项目类别:
Unveiling the chromosomal address of intact HIV clones to provide insights into persistence
揭示完整 HIV 克隆的染色体地址,以提供对持久性的见解
- 批准号:
9889887 - 财政年份:2019
- 资助金额:
$ 23.1万 - 项目类别:
An ex vivo model to predict outcomes and probe mechanism of anti-reservoir agents
预测抗储库药物结果和探讨机制的离体模型
- 批准号:
8930064 - 财政年份:2014
- 资助金额:
$ 23.1万 - 项目类别:
An ex vivo model to predict outcomes and probe mechanism of anti-reservoir agents
预测抗储库药物结果和探讨机制的离体模型
- 批准号:
8842406 - 财政年份:2014
- 资助金额:
$ 23.1万 - 项目类别:
相似海外基金
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:
10682185 - 财政年份:2023
- 资助金额:
$ 23.1万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
475843 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
474485 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10683329 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10481430 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
- 批准号:
nhmrc : 1196520 - 财政年份:2021
- 资助金额:
$ 23.1万 - 项目类别:
Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10260234 - 财政年份:2021
- 资助金额:
$ 23.1万 - 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10548114 - 财政年份:2021
- 资助金额:
$ 23.1万 - 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
- 批准号:
10400318 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial)
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)
- 批准号:
449805 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Studentship Programs